<DOC>
	<DOCNO>NCT01799538</DOCNO>
	<brief_summary>Background : - Lymphangioleiomyomatosis ( LAM ) rare type lung disease occur almost exclusively woman . In LAM , muscle tissue grow lung start block flow air . It progressive disease , severe case may require lung transplant . One possible treatment improve breathe people LAM inhale albuterol . Albuterol give meter dose inhaler ( MDI ) nebulizer . Researchers want compare method see method best improves lung function woman LAM . Objectives : - To see whether nebulizer MDI good improve lung function woman LAM . Eligibility : - Women least 18 year age impair lung function LAM . Design : - Participants screen physical exam medical history . No lab test need study . - Participants 3-day overnight stay National Institutes Health . Those use long-acting inhaler stop take drug 1 week study . - Participants receive either nebulizer two four puff inhaler . Four puff albuterol high dose normally prescribe , test study . - Participants treatment around time day 3 day . Before take albuterol , participant lung function test .</brief_summary>
	<brief_title>Nebulized Inhaled Albuterol Lymphangioleiomyomatosis</brief_title>
	<detailed_description>We report approximately one third patient lymphangioleiomyomatosis ( LAM ) airflow obstruction respond bronchodilator albuterol , Beta2-adenergic receptor agonist , increase force expiratory flow one second ( FEV1 ) 12 % 200 ml baseline value . Others however , question finding , report instead , low rate response six percent . Contrasting study , study albuterol administer meter dose inhaler whereas give nebulizer . We propose measure change lung function administration albuterol , respectively meter inhaler nebulizer , 3 consecutive day 150 LAM subject . Our hypothesis albuterol administer nebulization produce great increase FEV1 two puff inhale albuterol . If hypothesis confirm , may recommend patient LAM airflow obstruction use method drug administration nebulizer , rather meter dose inhaler .</detailed_description>
	<mesh_term>Lymphangioleiomyomatosis</mesh_term>
	<mesh_term>Bronchodilator Agents</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnosis LAM either tissue biopsy , evidence lung organ involvement ( renal angiomyolipomas , chylous effusion , lymphangioleiomyomas ) , high serum level vascular endothelial growth factor D ( VGEFD ) ( 1 ) diagnosis TSC associate cystic lung lesion . Age 18 year Evidence airflow obstruction : FEV1/VC ratio &lt; fifth percentile predict normal FEV ( 1 ) &lt; 80 % predict normal value . EXCLUSION CRITERIA : Subjects exclude study meet one follow criterion : History hypersensitivity albuterol component . Moderate large pleural effusion History seizures Inability withhold bronchodilator 24 hour Cognitive Impairment Age less 18 year Male sex Statuspost lung kidney transplantation Pregnant breast feeding ( woman childbearing potential undergo blood urine pregnancy test Protocol 95H0186 ) . Treatment monoaminoxidase inhibitor , tricyclic antidepressant Betaadrenergic receptor antagonist long act anticholinergic bronchodilator unable discontinue least seven day enrollment . Patients URI , uncontrolled hyperthyroidism severe gastroesophageal reflux . Major systemic disease ( i.e. , malignancy ; myocardial infarction unstable angina ; type 1 diabetes , severe hypertension ; liver cirrhosis ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 28, 2017</verification_date>
	<keyword>Albuterol</keyword>
	<keyword>Bronchodilator</keyword>
	<keyword>Nebulizer</keyword>
	<keyword>Metered Dose Inhaler</keyword>
</DOC>